Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Intra-Cellular Therapies (ITCI) reported a Q4 loss of $0.16 per share, which was larger than the Zacks Consensus Estimate of a $0.05 loss. However, the company topped revenue estimates.
February 21, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intra-Cellular Therapies reported a larger-than-expected Q4 loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.05 loss. Despite this, the company exceeded revenue expectations.
The larger-than-expected loss per share is likely to negatively impact ITCI's stock price in the short term, despite the positive news of exceeding revenue estimates. Investors often react more strongly to earnings per share results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100